• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

    2020-06-08 05:23:46IlariaLenciMartinaMilanaGiuseppeGrassiTommasoManziaCarloGaziaGiuseppeTisoneRobertaAngelicoLeonardoBaiocchi
    World Journal of Gastroenterology 2020年18期

    Ilaria Lenci, Martina Milana, Giuseppe Grassi, Tommaso M Manzia, Carlo Gazia, Giuseppe Tisone,Roberta Angelico, Leonardo Baiocchi

    Abstract Hepatitis B virus (HBV) recurrence after liver transplantation (LT) has been described more than 50 years ago. Similarly, to other clinical conditions, in which impairment of host immune defense favors viral replication, early reports described in details recurrence and reactivation of HBV in liver transplant recipients. The evidence of a possible, severe, clinical evolution of HBV reappearance in a significant percentage of these patients, allowed to consider,for some years, HBV positivity a contraindication for LT. Moving from the old to the new millennium this picture has changed dramatically. Several studies contributed to establish efficient prophylactic protocols for HBV recurrence and with the advent of more potent anti-viral drugs an increased control of infection was achieved in transplanted patients as well as in the general immunecompetent HBV population. Success obtained in the last decade led some authors to the conclusion that HBV is now to consider just as a “mere nuisance”.However, with regard to HBV and LT, outstanding issues are still on the table: (1)A standard HBV prophylaxis protocol after transplant has not yet been clearly defined; (2) The evidence of HBV resistant strains to the most potent antiviral agents is claiming for a new generation of drugs; and (3) The possibility of prophylaxis withdrawal in some patients has been demonstrated, but reliable methods for their selection are still lacking. The evolution of LT for HBV is examined in detail in this review together with the description of the strategies adopted to prevent HBV recurrence and their pros and cons.

    Key words: Liver transplant; Hepatitis B virus; Viral recurrence; Prophylaxis;Minimization; Antiviral drug

    INTRODUCTION

    The hepatitis B virus (HBV) is a small DNA virus belonging to theHepadnaviridaefamily[1]. Despite the adoption, in several countries, of an extended vaccination campaign starting in 1992, HBV infection still represents an important health problem with 350-400 million people infected in the world[2]. Without treatment, at least one third of patients are estimated to progress to significant liver disease, including endstage liver cirrhosis and tumors. In fact, the natural history of HBV liver disease includes a spectrum of clinical conditions ranging from a non-frequent fulminant hepatitis to HBV-related hepatocellular carcinoma and/or end-stage liver disease[3,4].While vaccination and the new antiviral drugs are effective, respectively, in avoiding HBV infection and preventing the most severe sequelae of HBV disease, liver transplantation (LT) remains the main therapeutic option in patients with more severe forms of HBV liver injury[5]. However, in the early 90's the possibility to offer LT to HBV candidates was an argument of debate. In fact, it was evident that HBV disease recurrence in the graft was severe in a significant proportion of patients[6]. Moreover,an aggressive clinical form of viral reactivation, named Fibrosing Cholestatic Hepatitis, was also described in nearly 25% of HBV transplanted patients, leading to a dramatic and rapidly progressive course[7]. Therapeutic advancement and prophylactic strategies against HBV radically changed this picture in the last three decades, allowing the consideration of HBV recurrence after LT to no longer be of concern. In this review we will describe HBV viral features, its natural history, and current outcome of HBV after LT.

    NATURAL HISTORY OF HBV

    HBV, a double stranded small DNA virus, replicating by reverse transcription, is able to convert its DNA in a covalently closed circular (ccc) form when reaching the hepatocyte's nucleus. cccDNA represents a mini-chromosome containing information for antigens (HBsAg, HBeAg, and HBcAg), X protein, and polymerase production[8].The infection route is mainly represented by vertical transmission in endemic areas.The estimated risk of acquiring the infection from an HBeAg+ mother is around 80%[9]. On the other hand, sexual or needle transmission are important paths in nonvaccinated adult patients of western countries[10]. Evolution of infection is dependent on the host, the viral genetics and virus/host interaction[3,11,12]. Vertical transmission at birth is associated (without peri-natal treatment) with a lifetime infection, usually with an immune-tolerant state[11]. This clinical situation is characterized by HBeAg positivity, high levels of HBV-DNA and normal liver function tests. Conversely, in adult normal subjects, immuno-tolerance usually lasts for 2-4 wk, the time span corresponding to the HBV incubation phase. Activation of the immune system against HBV determines: (1) Decreased HBV-DNA levels; (2) Increased liver inflammation;and (3) Elevation of serum levels of liver function tests. These features characterize the immune-active phase. This stage may evolve into: (1) Infection resolution with production of high titers of HBsAb (this target is reached by more than 90% of healthy adult individuals within 6 mo of initial HBV contact); (2) Fulminant hepatitis (rarely,≤ 0.5%); or (3) HBsAg persistence and evolution to chronic hepatitis[4]. During chronic hepatitis, the seroconversion to the HBeAg negative state (with development of HBeAb titer) represents an important achievement as it corresponds to decreased levels of HBV-DNA, liver inflammation and injury[13-15]. Moreover, HBeAg seroconversion with the consequent drop in HBV-DNA serum levels has been related to reduced fibrosis progression, histological staging, and onset of cirrhosis and hepatocellular carcinoma[16-18]. A subject with an acquired HBeAg negative state is usually defined as an inactive HBV carrier, referring to a remission state of the liver disease. Unfortunately, seroreversion to an HBeAg positive condition may occur over time (in approximately 20% of patients), also transiently, leading to a “de novo”immune-active inflammatory stage. Moreover, HBeAg loss (both spontaneous and drug induced) may determine selection in the host of pre-core mutants of HBV (not producing HBeAg). These strains are not affected, during their replicative phases, by anti-HBe antibodies, thus they determine progression of liver injury in approximately 10 to 30% of patients obtaining HBeAg loss[3,5,19]. The main clinical and virological features, in the different phases of HBV chronic infection, are reported in Table 1.From the above, it is evident that host-immune-system/virus interaction is a major determinant of the presence and severity of liver injury. This result is far more evident in subjects undergoing immune system changes related to biological or immunosuppressive therapies, including the majority of transplanted patients. In this setting severe reactivation of HBV is an element of concern[20].

    HBV DURING IMMUNE SYSTEM SUPPRESSION OR MODIFICATION (DRUG-INDUCED IMPAIRMENT OF THE IMMUNE SYSTEM AS A RISK FACTOR FOR HBV REACTIVATION)

    Reactivation of HBV is represented by sudden reappearance or increase of viral DNA in the serum of a patient with a resolved or clinically silent HBV infection[20]. This condition, which may also occur spontaneously, has been reported more frequently in patients undergoing immunosuppressive therapy for malignant or non-malignant disease[21]. In an early study in non-Hodgkin lymphoma patients under chemotherapy,HBV reactivation accounted for 72% of cases in HBsAg positive subjects[22]. More importantly, viral reappearance was also observed in HBsAb/HBcAb or only HBcAb positive subjects, thus suggesting the possibility of HBV reactivation also in conditions in which the infection was considered resolved in the past. Further studies also demonstrated HBV reappearance in non-neoplastic clinical settings such as Crohn's disease[23]or rheumatologic affections[24]. Treatment with biological agents,such as B-cell depleting (i.e., rituximab) or anti-tumor necrosis factor drugs(infliximab), carries a significant risk of HBV reactivation[25]. However, standard steroid treatment may also be responsible for HBV reappearance[26]. Evolution of viral reactivation is generally thought to occur in three separate phases[20,21]. At the beginning, a rise in HBV-DNA (at least ten-fold in comparison with baseline values) is observed during immunosuppressant treatment. In the second phase, when drugs are tapered or discontinued, the inflammatory damage begins, being triggered by the host immune defense that is also, in part, restored. In the last phase, the liver damage is repaired or may progress to end-stage liver failure. The evidence of a possible dramatic evolution of HBV reactivation in liver failure prompted the adoption of strategies to counteract this preventable occurrence. First of all, an adequate screening for HBV virus, including HBcAb, is proposed in individuals undergoing chronic therapy with immunologic modifiers. Secondly, antiviral agents able to prevent or cure this clinical condition are administered according to both viral and patient's features[27-29]. However, the clinical strategies commonly employed to prevent HBV reinfection are still lacking significant scientific evidence[27]. Therefore, the question of the best approach in different clinical scenarios remains open.

    Finally, the most important clinical setting in which HBV reappearance is a relevant issue is that of transplant. Transplanted patients usually require long-term high-dose immunosuppression to prevent rejection. In HBsAg positive patients undergoing bone marrow transplantation, HBV reactivation accounts for nearly the totality of cases[30]. Even in HBsAb/HBcAb+ subjects, reappearance of active HBV is not rare,accounting for nearly 20% of cases[31]. Starting from the early eighties, HBV reactivation was reported to be very frequent in the setting of kidney and heart transplantation, and it was characterized by the insurgence of HBV chronic hepatitis[20]. Indeed, HBV reactivation or recurrence also represents an important issue in liver transplanted patients. These subjects, in fact, share the same immunosuppressive need as other transplanted patients but, at the same time, are suffering the most important sequelae of HBV before surgery. This setting probably represents the most important clinical scenario in which dramatic HBV resurgence was observed

    Phase 1: lmmune tolerant Phase 2: lmmune active Phase 3: Asymptomatic carrier Phase 4: HBV reactivationand prophylactic measures were firstly pursued. At the same time, LT was the setting in which the risk of transplant with anti-core-HBV positive liver graft was identified.

    Table 1 Main virological and biochemical features in the different clinical phases of chronic hepatitis B in HBsAg+ patients

    HBV RECURRENCE IN THE EARLY TIMES OF LIVER TRANSPLANTATION (THE PURSUIT OF AN EFFECTIVE PROPHYLACTIC STRATEGY)

    HBV recurrence/reactivation after LT was already recognized almost 50 years ago[32].In the early 90's the feasibility of LT in HBV patients remained a crucial question since several reports observed viral recurrence in nearly all transplanted subjects, with an aggressive course in the larger part of them. While graft replacement was able to transiently reduce viral load, viral resurgence in the course of immunosuppression was related to significant liver damage and cirrhosis development[6,33]. So, at that time,LT in HBsAg positive patients was considered a high risk procedure for graft and patient loss, with an unacceptable hazard in particular in HBeAg+ subjects[34]. The disappointing results, and the need to pursue a solution for HBV patients with endstage liver disease, stimulated the research for a possible prophylactic therapy after LT. In a pioneering study conducted at Paul Brousse Hospital (Villejuif, France) in the eighties, an extended passive immune-prophylaxis was tested in HBsAg positive patients after LT[35]. Despite the monthly HBsAb immunoglobulin (HBIG)administration, 29% of patients experienced HBsAg and HBV-DNA reappearance in serum, however these data demonstrated the possibility to reduce HBV recurrence after LT. In a further European retrospective study on 372 HBV liver transplanted patients (between 1977 and 1990), a reduced rate of HBV reactivation was statistically associated with the absence of HBV-DNA before transplant and again to long-term passive immune prophylaxis with HBIG[36]. The exact mechanisms of the beneficial effects of immunoglobulin in this setting are not completely clear at present. Both reduced deletion of infected hepatocytes and prevention of viral aggression of liver cells have been suggested as possible effects[37]. Starting from the mid 90's, evidence was gathered on the role of lamivudine (Lam) treatment in repressing HBV replication[38,39]. Since, at that time, only HBIG-based prophylaxis was available after LT, and this therapy was a life-long, suboptimal, expensive treatment, the evaluation of the Lam effect in this clinical setting began. In an English study, 17 HBsAg positive patients were enrolled to receive Lam 4 wk before liver transplant and to continue 1 year thereafter[40]. Twelve out of seventeen patients were transplanted. In them, Lam induced a loss of HBsAg and undetectable HBV-DNA serum levels within 4 wk of treatment and after transplant. Moreover, liver histology did not show features suggesting HBV recurrence after LT, and these results were obtained without concomitant HBIG immune prophylaxis. Unfortunately, in the same study, selection of a resistant strain to Lam was observed in one patient after 20 wk of treatment. This occurrence was characterized by reactivation of HBV and evidence of chronic hepatitis on liver tissue after 1 year. Similar to that observed in HIV therapy[41], HBV strains not-responding to Lam were characterized by mutation of polymerase at the highly conserved YMDD motif[42-44]. With regard to liver transplanted HBV patients,extended follow up of Lam resistant patients was lately reported. Resistance to Lam began to occur, typically, six months after its introduction and was sometimes characterized by severe disease recurrence[45,46]. A combination of Lam therapy with HBIG was then attempted in order to further reduce HBV recurrence after LT. In a study, fourteen HBsAg positive LT patients were treated with Lam plus HBIG[47]. In a median follow-up of one year, all patients were HBV-DNA negative in serum, thus demonstrating the superiority of combination therapy in comparison with monotherapy with either Lam or HBIG. These data were also confirmed in a study with an extended (average 31 mo) follow-up[48]. Thus, the past millennium ended with the positive perspective that prevention of HBV recurrence/reactivation in HBsAg transplanted subjects was feasible. On the basis of these results, the possible exclusion of HBV subjects from transplant lists was largely reexamined.

    HBV RECURRENCE/REACTIVATION AFTER LIVER TRANSPLANTATION IN THE THIRD MILLENNIUM (TESTING NEW THERAPEUTIC APPROACHES AND DRUGS)

    The efficacy of passive immunization, in association with Lam, was again demonstrated in retrospective studies after the year 2000[49,50]. However, since this strategy was flawed by the relevant cost of HBIG and the need of life-long administration, the possibility to induce active immunization in HBV liver transplanted patients was examined.

    HBV vaccination

    In a study on 17 HBsAg+, HBeAg and HBV-DNA negative liver transplanted patients(after at least 18 mo of HBIG treatment), the double dose administration of HBV vaccine at baseline, 1 and 6 mo was tested[51]. After vaccination 84% of patients developed an HBsAb titer. During a further follow-up of 14 mo, HBsAg reappearance was not observed. These positive results were not replicated in a following study in which three reinforced and sequential cycles of HBV vaccination determined only a 17.6% HBsAb seroconversion in HBV transplanted patients[52]. In an editorial in the same journal, the limits of this strategy in transplanted patients were discussed,underscoring the scarce vaccine efficacy during immunosuppression and the long time needed to reconstitute the immune system after its depression[53]. In conclusion, it was confirmed that HBIG and antiviral therapy were regarded as the most appropriate measures against HBV recurrence after LT[54].

    Adefovir dipivoxil

    With regard to antiviral agents, in those years, a new drug implemented the armamentarium for the therapy of HBV. Adefovir dipivoxil (ADV), a nucleotide analog inhibiting viral reverse transcriptase that was abandoned for treatment of HIV because of kidney damage when used at high dose, was licensed for HBV treatment since it was active at lower, non-toxic levels for this virus (10 mg/d). ADV treatment in the majority of immune-competent HBsAg patients (both HBeAg positive or negative) determined a clear reduction of HBV-DNA, improvement of liver histology,and normalization of liver enzymes after a 48 wk course[55,56]. Moreover, emergence of ADV resistant mutants was not observed during these trials. Despite the fact that possible long-term viral resistance to ADV remained to be assessed, the efficacy of this new antiviral drug allowed hope for a new era in which HBV could be regarded as just a “mere nuisance”[57]. Soon, ADV was employed for the treatment of Lam resistant HBV after transplant[58]. Again, a significant improvement of liver function was recorded in nearly 90% of patients, and no resistant HBV strains were selected after 48 wk of therapy. However, ADV viral resistance was then observed with prolonged follow-up[59,60]. This was characterized by a novelN236Tmutation of HBV polymerase.In spite of this, the clinical evolution in patients was not worrisome since these ADV resistant strains were easily suppressed by Lam concomitant therapy. On the base of these findings, a possible Lam + ADV concomitant treatment for HBV was suggested[61]. Data from a systematic review including 2162 HBV LT patients[62]identified the following as possible risk factors for HBV recurrence: (1) Being HBVDNA positive at transplant (8.5%vs4%); (2) Administration of low dose HBIG in the first week after LT (6.1%vs3.5%); and (3) Combination therapy with HBIG + LamvsHBIG + ADV (6.1%vs2%). This picture was destined to undergo further changes with the advent of new nucleos(t)ide analogues with high genetic barriers.

    New high genetic barrier nucleos(t)ide analogues.

    Starting from 2012, entecavir (ETV) and tenofovir dipivoxyl (TDF) were proposed by several guidelines as a first line of treatment for chronic HBV hepatitis[5,63]. In fact, both drugs were demonstrated to be very effective in clinical studies, to have an excellent safety profile, and to be affected by a minimal or absent emergence of resistant HBV strains[64-68]. In a systematic review[69]on nucleos(t)ide analogues for HBV prophylaxis after LT, the comparison between Lam + HBIGvsthe association of ETV or TDF with HBIG demonstrated the superiority of the latter treatments (HBV recurrence rate 6.1%vs1%,P< 0.001). Moreover, in the same analysis, preliminary data evidenced slightly better results with either ETV or TDF monotherapy (after HBIG discontinuation) in comparison with the canonical Lam + HBIG prophylaxis (HBV recurrence rate 3.9%vs6.1%, difference not statistically significant). These findings introduced the concept of a possible minimization of HBV prophylaxis after LT, stimulating research with this target.

    TOWARD HBV PROPHYLAXIS MINIMIZATION AFTER LT

    Several strategies have been designed to minimize HBV prophylaxis after LT. The most relevant are described in the following subparagraphs with the corresponding results. Main studies on this issue are also summarized in Table 2.

    HBIG dose reduction

    Since long-term administration of HBIG was a critical point for its high cost, that would easily reach $100.000/pts/year[70], several attempts were carried out to reduce HBIG administration and acceptable results obtained. In a 2004 study conducted in our Unit (Liver Transplant Center, University of Rome Tor Vergata), we evaluated the possibility to prevent HBV recurrence after LT by administering HBIG on demand(when HBsAb serum levels were ≤ 70 IU/L) instead of the standard monthly administration[71]. Moreover, in the same study, two different HBIG doses (5000 IU or 2000 IU) were employed. In eleven HBV patients, at low risk for reactivation (HBsAg,HBV-DNA negative) and under concomitant Lam therapy, this strategy did not determine any HBV reactivation for 1 year follow up. On the other hand, the treatment based on administration of 2000 IU HBIG on demand reduced the cost of passive immune-prophylaxis by more than 50%. In 2007, the Australasian Liver Transplant Study Group assessed the association of very-low HBIG doses (400-800 IU)+ Lam on HBV recurrence after LT[72]. This strategy accounted for a modest HBV recurrence risk of 4% in 5 years, and the results were considered highly satisfactory since the majority of patients (85%) were HBV-DNA positive at transplant.

    High-genetic barrier nucleos(t)ide analogues monotherapy

    The advent of high-genetic barrier nucleos(t)ide analogues ETV and TDF, allowed speculation on a possible prophylaxis without HBIG. ETV monotherapy, tested on 80 patients undergoing LT for HBV, was able to suppress HBV-DNA (under the lower detection limit) in nearly 99% of cases after 24 mo[73]. Extended follow up of this study(8 years) demonstrated a 92% loss of HBsAg, while HBV-DNA was undetectable in all[74]. On the other hand, discontinuation of HBIG in transplanted patients treated with TDF + HBIG did not change any viral or patient profile in a 72 wk follow-up[75].Good results with either ETV and TDF were also replicated in other studies[76,77]. In a 5-year follow up in patients discontinuing HBIG and commencing either ETV or TDF after LT, HBsAg+ seroconversion occurred in 8% of cases, while HBV-DNA reappearance was not observed[78]. On the basis of these results, the most authoritative guidelines in the field now contemplate ETV or TDF monotherapy as an efficient prophylactic measure in subjects at low risk of HBV recurrence after LT[78,79].

    Complete withdrawal of HBV prophylaxis

    In the past years, our group examined a more radical approach to HBV prophylaxis minimization. This was characterized by the complete withdrawal of antiviral drugs in well selected HBV transplanted patients. We started with the assumption that reappearance of HBV after transplantation was dependent on the presence of cccDNA in the graft. Contrary to a North American study, (including several HBeAg/HBVDNA+ patients at LT) in which total HBV-DNA and cccDNA were detected in liver tissue in 83% and 18% of cases, respectively[80], in a preliminary evaluation of HBsAg patients transplanted in our center, only 1 out of 44 was found to be positive for cccDNA[81]. Among those that were negative for liver ccc-DNA, 30 were selected and underwent sequential withdrawal of HBIG and Lam. The majority of patients (83%,n= 25) did not experience any HBV recurrence in a median follow up longer than 2 years. Five patients came back to an HBsAg positive status. Prompt resumption of HBV prophylaxis allowed infection control, avoiding any significant clinical impairment[82]. From this study, we concluded that complete withdrawal of HBV prophylaxis after LT was feasible in patients with negative serum HBV-DNA and tissue cccDNA at transplant. An editorial, in the same journal, wisely observed that the time had come for an individualized prophylaxis in HBV transplanted patients[83].In fact, recurrence of HBV was mainly reported in patients who were HBV-DNA positive at transplant (> 100.000 copies/mL) and/or HBeAg+[36,72,84]. On the other hand, those not falling in the above category were considered at low risk for HBV recurrence. In this perspective, the target of HBV-DNA negativity was to be pursued before transplant in order to perhaps minimize prophylaxis after grafting. Conversely,for high-risk patients (HBeAg, HBV-DNA positive), more robust antiviral protocols were to be considered.

    Table 2 Main studies examining prophylaxis minimization in hepatitis B virus liver transplanted patients, employing different approaches

    More recently, data on longer (6-year) follow up of this original cohort were published by our group[85]. Only 3 patients needed prophylaxis resumption (10%). Of the whole cohort, 93% remained HBsAg negative and 100% had undetectable HBVDNA. More interestingly, 60% of patients spontaneously developed an HBsAb titer >10 IU/L. This was probably related to the minimization or withdrawal of antirejection therapy that is routinely pursued in our center in patients transplanted for several years. Comment on this study appeared in a new editorial[86]. While these data were encouraging, it underscored that limits remained in the identification of low risk patients. cccDNA techniques, in fact, needed to be standardized to be widely and consistently applicable in clinical settings, but on the other hand, extra-hepatic HBV reservoirs were still a possible issue of concern.

    CONCLUSION

    Several important achievements were obtained in the last fifty years with regard to HBV liver transplanted patients. The original exclusion of these subjects from LT waiting lists, due to poor outcome, was counteracted by the adoption of effective measures to prevent HBV recurrence. At present, high genetic barrier anti-viral drugs are giving an important contribution in transplanted patients, as well as in the HBV immune-competent population. Recently, tenofovir alafenamide, a TDF analog with improved renal safety and increased ability to reduce alanine aminotransferase, was employed in LT patients with good results[87]. However, of concern, HBV mutants with resistance to TDF (the drug with the highest genetic barrier) were recently identified, underscoring the need of a new generation of HBV agents to be employed,at least, as a rescue therapy[88]. The future of LT for HBV is not completely predictable at this stage. It will, however, depend on the global burden of HBV and the possible discovery of HBV eradicating drugs.

    亚洲欧美日韩东京热| 午夜久久久久精精品| 18+在线观看网站| 亚洲色图av天堂| 亚洲 国产 在线| 国产高清视频在线观看网站| 久久午夜亚洲精品久久| 国产综合懂色| 国产三级中文精品| 久久久久久久久大av| 啪啪无遮挡十八禁网站| 亚洲不卡免费看| 亚洲欧美日韩东京热| 午夜影院日韩av| 久久久久久国产a免费观看| 成年人黄色毛片网站| 国产在视频线在精品| 少妇熟女aⅴ在线视频| av在线观看视频网站免费| 精品久久国产蜜桃| 99精品久久久久人妻精品| 国产色爽女视频免费观看| 免费av不卡在线播放| 精品久久久久久久久亚洲 | 欧美精品啪啪一区二区三区| 国产不卡一卡二| or卡值多少钱| 性欧美人与动物交配| 国产精品不卡视频一区二区| 国产真实伦视频高清在线观看 | 色综合色国产| 免费av毛片视频| 欧美黑人巨大hd| 欧美成人免费av一区二区三区| 亚洲无线观看免费| av国产免费在线观看| 少妇裸体淫交视频免费看高清| 很黄的视频免费| 麻豆一二三区av精品| 成人毛片a级毛片在线播放| 美女高潮喷水抽搐中文字幕| 禁无遮挡网站| 成人一区二区视频在线观看| 日韩欧美国产一区二区入口| 欧美一区二区国产精品久久精品| 国产精品美女特级片免费视频播放器| 亚洲成av人片在线播放无| 男人舔奶头视频| a级毛片a级免费在线| 久99久视频精品免费| 免费人成在线观看视频色| 国产免费一级a男人的天堂| 丰满人妻一区二区三区视频av| 97热精品久久久久久| 国产av一区在线观看免费| 婷婷精品国产亚洲av| 午夜a级毛片| 亚洲aⅴ乱码一区二区在线播放| 亚洲欧美激情综合另类| 欧美绝顶高潮抽搐喷水| 日本 av在线| 啪啪无遮挡十八禁网站| 久久久久久久亚洲中文字幕| 男女啪啪激烈高潮av片| 一个人免费在线观看电影| 成人二区视频| 在线观看66精品国产| 久久亚洲精品不卡| 男人和女人高潮做爰伦理| 又黄又爽又刺激的免费视频.| 国产熟女欧美一区二区| 亚洲精品粉嫩美女一区| 桃色一区二区三区在线观看| 成人国产综合亚洲| 国产精品av视频在线免费观看| 91久久精品国产一区二区成人| 一卡2卡三卡四卡精品乱码亚洲| 日韩,欧美,国产一区二区三区 | 老师上课跳d突然被开到最大视频| 三级男女做爰猛烈吃奶摸视频| av国产免费在线观看| 99国产精品一区二区蜜桃av| 一卡2卡三卡四卡精品乱码亚洲| 亚洲色图av天堂| www.色视频.com| 成人无遮挡网站| 午夜久久久久精精品| 亚洲第一区二区三区不卡| 久久人人爽人人爽人人片va| 美女 人体艺术 gogo| 久久久久久久久中文| 最好的美女福利视频网| 日韩av在线大香蕉| 国产在线精品亚洲第一网站| 三级国产精品欧美在线观看| 成人特级av手机在线观看| 亚洲人成伊人成综合网2020| 成人国产综合亚洲| 亚洲国产欧洲综合997久久,| 久久久国产成人免费| 美女被艹到高潮喷水动态| 欧美日韩黄片免| av中文乱码字幕在线| 久久久午夜欧美精品| 中文字幕av成人在线电影| 黄片wwwwww| 亚洲第一区二区三区不卡| av中文乱码字幕在线| 他把我摸到了高潮在线观看| 少妇被粗大猛烈的视频| 九九久久精品国产亚洲av麻豆| 国产国拍精品亚洲av在线观看| 国产免费av片在线观看野外av| 午夜福利在线在线| 身体一侧抽搐| 亚洲国产精品合色在线| 国产精品野战在线观看| 午夜日韩欧美国产| 国产精品综合久久久久久久免费| 99热网站在线观看| 亚洲无线在线观看| 国产精品自产拍在线观看55亚洲| 成年免费大片在线观看| 又紧又爽又黄一区二区| 91久久精品国产一区二区三区| 欧美丝袜亚洲另类 | videossex国产| 国内久久婷婷六月综合欲色啪| 日韩中文字幕欧美一区二区| 噜噜噜噜噜久久久久久91| 麻豆av噜噜一区二区三区| 看免费成人av毛片| 国产av不卡久久| 午夜激情欧美在线| 在线观看舔阴道视频| 91久久精品电影网| 最近中文字幕高清免费大全6 | 村上凉子中文字幕在线| 一区二区三区四区激情视频 | 免费看日本二区| 婷婷亚洲欧美| 国产私拍福利视频在线观看| 最新在线观看一区二区三区| av福利片在线观看| 嫩草影院精品99| 国产v大片淫在线免费观看| 免费无遮挡裸体视频| 美女高潮喷水抽搐中文字幕| 男人狂女人下面高潮的视频| 午夜福利在线观看免费完整高清在 | 久久久久精品国产欧美久久久| 一级黄色大片毛片| 变态另类丝袜制服| 欧美极品一区二区三区四区| 91久久精品电影网| 露出奶头的视频| 毛片一级片免费看久久久久 | 色综合婷婷激情| 亚洲中文字幕日韩| 亚洲真实伦在线观看| 天堂√8在线中文| a在线观看视频网站| 国内久久婷婷六月综合欲色啪| 色哟哟哟哟哟哟| 乱人视频在线观看| 亚洲av不卡在线观看| 欧美三级亚洲精品| 精品免费久久久久久久清纯| 国产探花在线观看一区二区| 搡女人真爽免费视频火全软件 | 夜夜夜夜夜久久久久| 99久久九九国产精品国产免费| 美女黄网站色视频| 极品教师在线视频| ponron亚洲| 精品免费久久久久久久清纯| 可以在线观看毛片的网站| 欧美日本亚洲视频在线播放| 日本 欧美在线| 啦啦啦观看免费观看视频高清| 国产精品福利在线免费观看| 久久久久九九精品影院| 亚洲va日本ⅴa欧美va伊人久久| 香蕉av资源在线| 亚洲人与动物交配视频| 99视频精品全部免费 在线| 亚洲精品国产成人久久av| 极品教师在线视频| 免费在线观看影片大全网站| 亚洲国产精品成人综合色| 天堂网av新在线| 欧美日本亚洲视频在线播放| 麻豆成人午夜福利视频| 国产高清不卡午夜福利| 欧美性猛交╳xxx乱大交人| 国产精品永久免费网站| 国产精品久久久久久亚洲av鲁大| videossex国产| 波多野结衣巨乳人妻| avwww免费| 在线免费十八禁| 国产精品国产高清国产av| 少妇的逼好多水| 91精品国产九色| 国产午夜福利久久久久久| 极品教师在线免费播放| 免费在线观看日本一区| 精华霜和精华液先用哪个| 国产欧美日韩一区二区精品| 亚洲经典国产精华液单| 国产黄色小视频在线观看| 一本精品99久久精品77| 搡老岳熟女国产| 午夜精品在线福利| 国内精品一区二区在线观看| 亚洲狠狠婷婷综合久久图片| 精品国内亚洲2022精品成人| 久久久久久久久大av| 亚洲成a人片在线一区二区| 国产老妇女一区| 99九九线精品视频在线观看视频| 国产探花在线观看一区二区| 99久久中文字幕三级久久日本| 欧美色欧美亚洲另类二区| 小说图片视频综合网站| 亚洲av第一区精品v没综合| 亚洲三级黄色毛片| 99久久中文字幕三级久久日本| 啦啦啦啦在线视频资源| 国产女主播在线喷水免费视频网站 | 啪啪无遮挡十八禁网站| 中文字幕av在线有码专区| 草草在线视频免费看| 欧美xxxx性猛交bbbb| 麻豆成人av在线观看| 99九九线精品视频在线观看视频| av专区在线播放| 久久99热这里只有精品18| 亚洲成a人片在线一区二区| 久久精品91蜜桃| 国产伦人伦偷精品视频| 在线国产一区二区在线| 香蕉av资源在线| 久久久国产成人精品二区| 两个人的视频大全免费| 美女cb高潮喷水在线观看| 国产伦在线观看视频一区| 欧美精品国产亚洲| 级片在线观看| 少妇丰满av| 51国产日韩欧美| 99视频精品全部免费 在线| 观看美女的网站| 欧美潮喷喷水| 香蕉av资源在线| 久久精品国产99精品国产亚洲性色| 国产一级毛片七仙女欲春2| av视频在线观看入口| 中文字幕av在线有码专区| 国产精品免费一区二区三区在线| 99热这里只有精品一区| 欧美日本亚洲视频在线播放| 在线免费观看不下载黄p国产 | 亚洲欧美激情综合另类| 悠悠久久av| 69av精品久久久久久| 亚洲成av人片在线播放无| 亚洲18禁久久av| 亚洲不卡免费看| 午夜福利18| 1024手机看黄色片| 亚洲电影在线观看av| 69av精品久久久久久| 欧美日本视频| 丰满乱子伦码专区| 国产高清三级在线| 色吧在线观看| 高清在线国产一区| 18禁黄网站禁片免费观看直播| 简卡轻食公司| 国产一区二区三区视频了| 亚洲黑人精品在线| 国产探花极品一区二区| 丰满乱子伦码专区| 欧美bdsm另类| 可以在线观看的亚洲视频| 欧美日韩综合久久久久久 | 亚洲在线观看片| 久久亚洲精品不卡| 精品久久久久久成人av| 少妇人妻一区二区三区视频| 啦啦啦啦在线视频资源| 大型黄色视频在线免费观看| 久久九九热精品免费| 老熟妇乱子伦视频在线观看| 亚洲欧美日韩卡通动漫| 老司机深夜福利视频在线观看| 国产成人福利小说| 日日夜夜操网爽| 日韩欧美三级三区| 久久国产精品人妻蜜桃| 我的女老师完整版在线观看| 中文字幕人妻熟人妻熟丝袜美| 精品人妻视频免费看| 精品无人区乱码1区二区| 人妻夜夜爽99麻豆av| 高清毛片免费观看视频网站| 久久香蕉精品热| 岛国在线免费视频观看| 亚洲va日本ⅴa欧美va伊人久久| 久久久精品欧美日韩精品| 国产精品电影一区二区三区| 久久人人爽人人爽人人片va| 亚洲精品456在线播放app | 久久久久久久久久久丰满 | 两人在一起打扑克的视频| 国产高潮美女av| 久久国内精品自在自线图片| 国产午夜福利久久久久久| 最后的刺客免费高清国语| 亚洲av五月六月丁香网| 欧美zozozo另类| 老司机深夜福利视频在线观看| 久久久精品欧美日韩精品| 国产伦精品一区二区三区四那| 免费电影在线观看免费观看| 乱码一卡2卡4卡精品| 午夜福利欧美成人| 久久午夜亚洲精品久久| 尾随美女入室| 久久久久久久久大av| 观看美女的网站| 国产久久久一区二区三区| 亚洲av五月六月丁香网| 哪里可以看免费的av片| 97超级碰碰碰精品色视频在线观看| 成人国产综合亚洲| 久久人人爽人人爽人人片va| 久久草成人影院| 亚洲中文字幕日韩| 黄色视频,在线免费观看| 国产综合懂色| 国产精品福利在线免费观看| 俺也久久电影网| 在线观看舔阴道视频| 99热网站在线观看| 97超级碰碰碰精品色视频在线观看| 伦理电影大哥的女人| 99在线人妻在线中文字幕| 91麻豆av在线| 午夜福利在线观看免费完整高清在 | 国产久久久一区二区三区| 一a级毛片在线观看| 91麻豆av在线| 精品国产三级普通话版| 亚洲不卡免费看| 久久这里只有精品中国| 内地一区二区视频在线| 91午夜精品亚洲一区二区三区 | 嫩草影院新地址| 欧美性感艳星| 麻豆av噜噜一区二区三区| 一区二区三区激情视频| 听说在线观看完整版免费高清| 欧美高清性xxxxhd video| 国产伦一二天堂av在线观看| 国产av在哪里看| 免费搜索国产男女视频| 在线播放国产精品三级| 久久热精品热| 搡老妇女老女人老熟妇| 精品一区二区三区av网在线观看| 美女大奶头视频| 久9热在线精品视频| 亚洲国产精品合色在线| 亚洲精品粉嫩美女一区| 欧美高清性xxxxhd video| 久久欧美精品欧美久久欧美| 欧美成人一区二区免费高清观看| 小蜜桃在线观看免费完整版高清| www.色视频.com| 欧美色欧美亚洲另类二区| 精品一区二区三区视频在线观看免费| 国产高清有码在线观看视频| 日日摸夜夜添夜夜添小说| 男女做爰动态图高潮gif福利片| 欧美xxxx性猛交bbbb| 国产精品久久久久久久电影| 最近视频中文字幕2019在线8| 午夜日韩欧美国产| 国产黄色小视频在线观看| 黄色配什么色好看| videossex国产| 欧美区成人在线视频| 桃红色精品国产亚洲av| 99久久久亚洲精品蜜臀av| 精品人妻熟女av久视频| 自拍偷自拍亚洲精品老妇| 久久久国产成人精品二区| 精华霜和精华液先用哪个| 亚洲avbb在线观看| 丰满人妻一区二区三区视频av| 淫妇啪啪啪对白视频| 久久精品影院6| 麻豆一二三区av精品| 亚洲最大成人av| 日日摸夜夜添夜夜添av毛片 | 日韩大尺度精品在线看网址| 亚洲精品国产成人久久av| 亚洲无线观看免费| 色播亚洲综合网| 在线a可以看的网站| 国产亚洲av嫩草精品影院| 波野结衣二区三区在线| 日韩亚洲欧美综合| 日韩一本色道免费dvd| 国产视频内射| 精品国产三级普通话版| 国产高清三级在线| 欧美日韩中文字幕国产精品一区二区三区| 亚洲,欧美,日韩| 狠狠狠狠99中文字幕| 国产白丝娇喘喷水9色精品| 一边摸一边抽搐一进一小说| 国产高潮美女av| 亚洲欧美激情综合另类| 男人舔奶头视频| 一级av片app| 搡女人真爽免费视频火全软件 | 国产亚洲精品av在线| 观看美女的网站| 网址你懂的国产日韩在线| 性色avwww在线观看| 两个人的视频大全免费| 国产亚洲欧美98| 午夜福利欧美成人| 99热这里只有是精品50| 日韩强制内射视频| 婷婷亚洲欧美| 国产精品嫩草影院av在线观看 | 欧美色视频一区免费| 男女啪啪激烈高潮av片| 亚洲精品456在线播放app | 真人做人爱边吃奶动态| 一夜夜www| 亚洲专区国产一区二区| 午夜精品久久久久久毛片777| 99国产极品粉嫩在线观看| 婷婷丁香在线五月| 日日撸夜夜添| av专区在线播放| 亚洲av一区综合| 国产黄片美女视频| 好男人在线观看高清免费视频| 波多野结衣高清无吗| 一级av片app| 精品一区二区免费观看| 美女被艹到高潮喷水动态| 日韩欧美免费精品| 人人妻人人澡欧美一区二区| x7x7x7水蜜桃| 久久亚洲精品不卡| 淫妇啪啪啪对白视频| a级毛片a级免费在线| 成人高潮视频无遮挡免费网站| 日本 欧美在线| 1000部很黄的大片| 麻豆精品久久久久久蜜桃| 久久精品久久久久久噜噜老黄 | 日韩欧美免费精品| 小说图片视频综合网站| 欧美xxxx性猛交bbbb| 18禁黄网站禁片免费观看直播| 国产在视频线在精品| 亚洲国产欧美人成| 欧美日韩瑟瑟在线播放| 亚洲四区av| 国产av在哪里看| 日本三级黄在线观看| 亚洲国产欧洲综合997久久,| 国产亚洲精品综合一区在线观看| 岛国在线免费视频观看| 国产一区二区三区视频了| 99热这里只有是精品在线观看| 久久亚洲精品不卡| 欧美潮喷喷水| 欧美激情在线99| 国产一区二区三区视频了| 97超级碰碰碰精品色视频在线观看| 国产主播在线观看一区二区| 黄色欧美视频在线观看| 男女之事视频高清在线观看| 全区人妻精品视频| 桃色一区二区三区在线观看| 久久久久久伊人网av| 小蜜桃在线观看免费完整版高清| 免费搜索国产男女视频| 欧美一区二区精品小视频在线| 女人被狂操c到高潮| 国产91精品成人一区二区三区| 真人做人爱边吃奶动态| 亚洲黑人精品在线| 日本免费一区二区三区高清不卡| 午夜福利成人在线免费观看| 久久精品影院6| 国产探花极品一区二区| 一本一本综合久久| 91av网一区二区| 淫妇啪啪啪对白视频| 免费观看人在逋| 日本黄色视频三级网站网址| 啦啦啦啦在线视频资源| 亚州av有码| 伦精品一区二区三区| 桃红色精品国产亚洲av| 色在线成人网| 精品久久久久久久久久免费视频| 超碰av人人做人人爽久久| 亚洲成人免费电影在线观看| 色视频www国产| 美女黄网站色视频| 欧美+日韩+精品| 99riav亚洲国产免费| 精品人妻偷拍中文字幕| 欧美日韩亚洲国产一区二区在线观看| 变态另类丝袜制服| 老熟妇乱子伦视频在线观看| 日韩 亚洲 欧美在线| 热99在线观看视频| 99久久精品一区二区三区| 色播亚洲综合网| 国产乱人视频| 高清在线国产一区| 久久久精品欧美日韩精品| 又紧又爽又黄一区二区| 两人在一起打扑克的视频| 我的女老师完整版在线观看| 国产伦一二天堂av在线观看| 国内精品宾馆在线| 97人妻精品一区二区三区麻豆| 亚洲人成网站高清观看| 男女之事视频高清在线观看| 悠悠久久av| 精品久久久久久成人av| a级毛片免费高清观看在线播放| 国产白丝娇喘喷水9色精品| 亚洲人与动物交配视频| www.色视频.com| 中国美白少妇内射xxxbb| 99riav亚洲国产免费| 国产三级在线视频| 九色国产91popny在线| 欧美日韩乱码在线| 亚洲成人久久性| 国产精品久久电影中文字幕| 欧美性猛交黑人性爽| 欧美日韩综合久久久久久 | 国产爱豆传媒在线观看| 久久精品国产亚洲av天美| 九九热线精品视视频播放| 在线观看66精品国产| 亚洲成a人片在线一区二区| 亚洲av美国av| 日韩精品中文字幕看吧| 51国产日韩欧美| 91麻豆精品激情在线观看国产| 尾随美女入室| 亚洲欧美日韩高清专用| 久久精品夜夜夜夜夜久久蜜豆| 亚洲中文日韩欧美视频| 高清毛片免费观看视频网站| 久久国产乱子免费精品| 日韩一区二区视频免费看| 久久天躁狠狠躁夜夜2o2o| 国产男靠女视频免费网站| 淫妇啪啪啪对白视频| 久久久久久久精品吃奶| 欧美又色又爽又黄视频| 久久久久久久亚洲中文字幕| 女人十人毛片免费观看3o分钟| 国产精品综合久久久久久久免费| 国内久久婷婷六月综合欲色啪| 极品教师在线免费播放| 麻豆久久精品国产亚洲av| 午夜福利成人在线免费观看| 亚洲精品国产成人久久av| 日韩中文字幕欧美一区二区| 特大巨黑吊av在线直播| 久久久久久大精品| 国产熟女欧美一区二区| 老司机福利观看| 日韩强制内射视频| 欧美日韩黄片免| 亚洲不卡免费看| 一级毛片久久久久久久久女| 国产高潮美女av| 天堂影院成人在线观看| 最近中文字幕高清免费大全6 | 久久午夜亚洲精品久久| 日韩精品有码人妻一区| 久久久久免费精品人妻一区二区| 1024手机看黄色片| 久久精品国产亚洲av香蕉五月| 国产伦在线观看视频一区| 在线免费十八禁| 91麻豆精品激情在线观看国产| 日本熟妇午夜| 国产中年淑女户外野战色| 精品午夜福利在线看| 国产精品98久久久久久宅男小说| 欧美3d第一页| 琪琪午夜伦伦电影理论片6080| 亚洲国产高清在线一区二区三| 欧美日韩亚洲国产一区二区在线观看| 久久久精品欧美日韩精品|